Labaton Keller Sucharow LLP Announces Expanded Securities Class Action Lawsuit Filed Against DexCom, Inc. and Certain Executives

Core Viewpoint - Labaton Keller Sucharow LLP has filed a securities class action lawsuit against DexCom, Inc. and certain executives, alleging misleading statements regarding the reliability and safety of their continuous glucose monitoring systems [1][4]. Summary by Sections Lawsuit Details - The lawsuit was filed on November 25, 2025, on behalf of the Boston Retirement System against DexCom and its executives, asserting claims under the Securities Exchange Act of 1934 [1]. - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025 [1]. Allegations - The complaint alleges that DexCom made unauthorized design changes to its CGM products, which rendered them less reliable and posed health risks to users [4]. - It is claimed that these undisclosed issues led to increased regulatory scrutiny and negatively impacted the company's sales and public statements regarding product reliability [4]. Impact on Stock Price - Following disclosures about the accuracy problems of DexCom's CGM devices, the company's stock price fell by $8.99 per share, or 11.8%, closing at $67.45 on September 19, 2025 [5]. Legal Representation - The Boston Retirement System is represented by Labaton Keller Sucharow LLP, which has a strong reputation in securities litigation and manages over $4.5 trillion in assets [8].